Genmab

	8/12 20:56 af E L	DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma (link)
	8/12 20:54 af E L	‘Double-Barreled’ Drug Shows Early Promise for Blood Cancer (link)
	8/12 20:26 af E L	slides - #ASH24 \| Alexey Danilov: epcoritamab monotherapy in patients with R/R #chroniclymphocyticleukemia: results from #CLL expansion and optimization cohorts of Epcore CLL-1 (link)
	8/12 20:25 af E L	Exploring New Frontiers in Chronic Lymphocytic Leukemia (CLL) Treatment: A Q&A With City of Hope’s Dr. Danilov (link)
	8/12 20:24 af E L	Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL - Epcoritamab - (link)
	8/12 20:23 af E L	Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis (link)
	8/12 17:17 af RLFB	I believe upside between 200% and 300% can be realized in the medium- to long-term, and that it can be significantly higher in the long run if some of the pipeline assets live up to the company’s expectations.
	8/12 16:11 af ProInvestorNEWS	Onsdag d. 11. december...... Genmab vil holde sin Forsknings- og Udviklingsopdatering og gennemgang af de data, der præsenteres i forbindelse med for American Society of Hematology, ASH’s, årlige møde. Begivenheden, der løber af stablen onsdag klokken 17, har ikke noget med det generelle program at gøre.
	8/12 16:05 af w	….og f orfatteren forventer ikke opt in
	8/12 16:04 af w	(link)
	8/12 16:03 af w	Genmab Is Too Attractive To Ignore
	8/12 11:53 af E L	yeah, and epco the lowest of the 3 here
	8/12 11:48 af Solsen	Looks manageable :-)
	8/12 11:42 af E L	(link)
	8/12 11:41 af E L	by chance this article today, shows- There are limited data on the use of G-CSF in anti-CD20 BsAbs. In a study of mosunetuzumab for R/R B-NHL, a total of 60/218 (27.5%) patients experienced a neutropenic event, and 41/60 patients (68.3%) received G-CSF, with a positive response in 39/41 patients (95.1%). A phase I trial of glofitamab noted that G-CSF was administered in 37 patients (21.6%), while a dose-expansion phase I/II study of epcoritamab noted that only 10.1% of patients required G-CSF
	8/12 11:40 af Solsen	Thanks EL
	8/12 11:32 af E L	"In the event of febrile neutropenia, patients should be evaluated for infection and managed with antibiotics, fluids and other supportive care, according to local guidelines." "Of the 105 patients who had neutropenia/neutrophil count decreased events, 61% received G-CSF to treat the events" (link)
	8/12 10:53 af Solsen	Only negative is neutropenia. Do we know what they are doing with that - treatment ?
	8/12 10:47 af E L	The Fixed duration regime is offcourse a response to glofitamab competition- this poster suggests it may be better to keep treating to progression (for some patients?) (link) @DrRaulCordoba #ASH24 Interesting study : “Treatment to progression vs FDT efficacy of #epcoritamab: a modeling and simulation study”
	8/12 10:38 af E L	slides- Fernando Martín Moro @Fer_martinmoro Fixed-Duration Epcoritamab + R2 in R/R Follicular Lymphoma: 2-Year Follow-up from Arm 2 Epcore NHL-2 Trial (link)
	8/12 10:21 af E L	the press release from AbbVie -- (link)
	8/12 08:55 af Solsen	2 års overlevelse i FL relapsed er 90% og er imponerende. Epco bliver et stort aktiv.
	8/12 08:48 af Henrikhot	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL). (link)" target='_new' title="(link)" style='color:#1C2736;'>(link) (link)" target='_new' title="(link)" style='color:#1C2736;'>(link)
	6/12 21:00 af E L	(link)

	6/12 20:24 af E L	Genmab @Genmab We are presenting new clinical data at #ASH24 across subtypes of non-Hodgkin’s lymphoma (#NHL), a type of cancer that affects the lymphatic system, usually found in the lymph nodes. Swipe to learn more about this disease and how it can affect patients. (link)
	6/12 16:58 af Riis7	Det hvis os bare en omgang ai de bruger;-) måske sælge Genmab og købe nogle ai aktier ;-) nvidia har vækst;-)
	6/12 15:58 af M_T_A	@Bulder hehe, synes dog tit at Simplty har værdiansættelser helt hen i vejret. :) Kigger man på forudsætningerne fra beregningen antager beregningen en FCF på nuværende 6 mia som vokser til underkanten af 20 mia i 2030, og fortsætter i samme tempo. Er dette en realistisk projektion? Hmm :D
	6/12 15:17 af Bulder	En fair value, der er til at forstå ;-) (link)
	6/12 13:06 af ProInvestorNEWS	Teknisk analyse på Genmab (link)
	5/12 18:00 af ProInvestorNEWS	Danmark har flere store virksomheder, som danskerne er stolte af, og som er blevet til folkeaktier. Men det seneste års tid har der været udfordringer, som har fået nogle danskere til at søge grønnere græsgange. Lyt med, når Helge Larsen kigger på udfordringerne hos to af folkeaktierne - nemlig Vestas og Genmab. (link)
	5/12 17:41 af E L	(link) promising #ClinicalTrials, most discussed among the oncologists on X - TRIMM-2 = Talq-Dara, Epcore= Epco, MajesTEC=Teclistamab, Auriga & AQUILA =Dara
	5/12 16:04 af E L	Japanese acasunlimab safety trial Completed (link)
	5/12 15:37 af ProInvestorNEWS	I videoen her gennemgår vi Genmab med 3-PointPlaybook-strategien. Her kigger vi på følgende punkter: 1. Er aktien solid? 2. Er aktien godt prissat? 3. Er timingen rigtig? (link)
	5/12 13:32 af lahn1	EL, you know we like your news bulletin.
	5/12 13:09 af gentogen	Uanset hvad vil jeg også gerne sige tusind tak EL for de mange informationer om Genmab. Som Solsen lige skrev, så er blot den sidste artikel jo monster interessant. Og der er sikkert andre end mig, der læser alle dine links, selv om vi er godt trætte af at vente på hexen...
	5/12 13:07 af Solsen	Imponerende data på tec og tal efter CAR-t relapse !
	5/12 12:59 af Darvin	;-)
	5/12 12:06 af E L	Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy (link)
	5/12 11:32 af E L	In hindsight, it would have been better if we had gotten bored of Genmab and become more silent here 2 years ago and sold the lot at 3000... In that light you should even be angry at all the writers for posting too much ;-)
	5/12 11:31 af E L	we used to keep ourselves busy with news on the royalty pipeline, Dara, amivantamab, teclistamab, talquetamab, kesimpta; there is still plenty of news on those, but the interest has disappeared here. Genmab's own pipeline does not produce that much news yet, data takes a long time.
	5/12 10:13 af Darvin	Undskyld - den med at ingen var glemt kunne misforståes. Jeg mente naturligvis at der var andre super skribenter end de nævnte. Ville blot ikke remse op. Undskyld hvis det blev tolket anderledes
	4/12 23:59 af Solsen	EL er uvurderlig. Vi står overfor ASH og efterfølgende et Genmab event. Så stay tuned.
	4/12 21:24 af Darvin	Hej E L og andre. Trist at der er blevet så forholdsvist stille i Genmab chatten. Selv skriver jeg heller ikk som tidligere, men pyt med det. E L - du er mere end guld værd, og ikke kun “værdsat”. Håber virkelig du holder ved. Ligesom Solsen, Bulder og flere andre. Ingen flere nævnt desværre, men heller INGEN glemt. Håber virkelig både Genmab (aktien) og vi andre får gejsten igen. NB! Er selv i den grad fortsat i og omkring Genmab, men trist at positivt afkast kun hentes i spekulative dispositio
	4/12 16:09 af E L	Genmab expands its pipeline with $630m Scancell deal (link)
	4/12 10:04 af E L	‘As bispecific antibodies change DLBCL treatment paradigm, Epkinly draws attention’ (link)
	4/12 09:27 af E L	Scancell Announces Genmab Exercises Option to a Second Commercial License Agreement (link)
	4/12 09:24 af transalp	Go morgen.. :)
	3/12 18:20 af E L	the last push upward went from 1515.5 to 1652 = 136.5dkk. This stint went from 1431 to 1567.5 = 136.5dkk. ;-)
	3/12 17:22 af E L	the GEN1042 trial in combination with radiotherapy / pembrolizumab set to Active, not recruiting - curious if we can get some info on that soonish (link)
	3/12 15:06 af E L	Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting / Mim8 (link)